Literature DB >> 17574398

Development of HSA-free formulations for a hydrophobic cytokine with improved stability.

Andrea Hawe1, Wolfgang Friess.   

Abstract

The goal was to characterize a hydrophobic cytokine with respect to oxidation and aggregation, as well as its adsorption to the container at different pH and ionic strength conditions. The tendency of the cytokine to adsorb on surfaces and its low solubility at physiological pH were the main challenges during the development of HSA-free formulations for the cytokine. When the formulation pH exceeded 5.5 precipitation led to significantly higher turbidity. This turbidity increase and elevated aggregation as determined by HP-SEC and DLS was more pronounced at higher glycine and NaCl concentrations. With rising pH protein adsorption was more distinct compared to pH 3.0. However, protein adsorption could be minimized by polysorbate 20 or the use of glass type I(+). FTIR revealed a reduced thermal stability at higher pH values indicated by a declining denaturation temperature. Five liquid formulations in the pH range 3.5-4.5 and five lyophilized formulations at pH 4.0-5.0 were stored for 6 months and the stability was evaluated with respect to aggregation and chemical modification. Liquid formulations at pH 3.5-4.0 and lyophilized formulations at pH 4.0-5.0 were most stable during 6 months at 2-8 degrees C.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574398     DOI: 10.1016/j.ejpb.2007.04.018

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

2.  Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2011-05-05       Impact factor: 4.200

3.  Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-05-25       Impact factor: 4.200

4.  Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation.

Authors:  Najmeh Mahjoubi; Mohammad Reza Fazeli; Rassoul Dinarvand; Mohammad Reza Khoshayand; Ahmad Fazeli; Mohammad Taghavian; Hossein Rastegar
Journal:  Adv Pharm Bull       Date:  2015-11-30

5.  Effect of Nonionic Surfactants (Dodecyl Maltoside and Polysorbate 20) on Prevention of Aggregation and Conformational Changes of Recombinant Human IFNβ_1b Induced by Light.

Authors:  Najmeh Mahjoubi; Ahmad Fazeli; Rassoul Dinarvand; Mohammad Reza Khoshayand; Maryam Shekarchi; Mohammad Reza Fazeli
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

Review 6.  Analytical Techniques for Structural Characterization of Proteins in Solid Pharmaceutical Forms: An Overview.

Authors:  Aljoša Bolje; Stanislav Gobec
Journal:  Pharmaceutics       Date:  2021-04-11       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.